Decoding the Intricacies of Statin-Associated Muscle Symptoms

IF 5.7 2区医学 Q1 RHEUMATOLOGY

Current Rheumatology Reports Pub Date : 2024-04-05 DOI:10.1007/s11926-024-01143-y

Tara Fallah Rastegar, Imtiaz Ahmed Khan, Lisa Christopher-Stine

{"title":"Decoding the Intricacies of Statin-Associated Muscle Symptoms","authors":"Tara Fallah Rastegar, Imtiaz Ahmed Khan, Lisa Christopher-Stine","doi":"10.1007/s11926-024-01143-y","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Hyperlipidemia is the major cardiovascular morbidity and mortality risk factor. Statins are the first-line treatment for hyperlipidemia. Statin-associated muscle symptoms (SAMS) are the main reason for the discontinuation of statins among patients. The purpose of this review is to guide clinicians to recognize the difference between self-limited and autoimmune statin myopathy in addition to the factors that potentiate them. Finally, treatment strategies will be discussed. This review mostly focuses on new data in the past 3 years.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Recent findings suggest that SAMS is a complex and multifactorial condition that involves mitochondrial dysfunction, oxidative stress, and immune-mediated mechanisms. Effective management of SAMS requires a thorough evaluation of the patient’s symptoms, risk factors, and medication history, as well as consideration of alternative treatment options.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>While statins are effective in reducing the risk of cardiovascular events, their use is associated with a range of adverse effects, including SAMS.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"62 1","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-024-01143-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

Hyperlipidemia is the major cardiovascular morbidity and mortality risk factor. Statins are the first-line treatment for hyperlipidemia. Statin-associated muscle symptoms (SAMS) are the main reason for the discontinuation of statins among patients. The purpose of this review is to guide clinicians to recognize the difference between self-limited and autoimmune statin myopathy in addition to the factors that potentiate them. Finally, treatment strategies will be discussed. This review mostly focuses on new data in the past 3 years.

Recent Findings

Recent findings suggest that SAMS is a complex and multifactorial condition that involves mitochondrial dysfunction, oxidative stress, and immune-mediated mechanisms. Effective management of SAMS requires a thorough evaluation of the patient’s symptoms, risk factors, and medication history, as well as consideration of alternative treatment options.

Summary

While statins are effective in reducing the risk of cardiovascular events, their use is associated with a range of adverse effects, including SAMS.

查看原文本刊更多论文

解密他汀类药物相关肌肉症状的复杂性

综述目的高脂血症是心血管疾病发病和死亡的主要风险因素。他汀类药物是治疗高脂血症的一线药物。他汀类药物相关肌肉症状（SAMS）是患者停用他汀类药物的主要原因。本综述旨在指导临床医生认识自限性他汀类药物肌病和自身免疫性他汀类药物肌病之间的区别，以及诱发这两种肌病的因素。最后还将讨论治疗策略。最新研究结果最新研究结果表明，SAMS 是一种复杂的多因素疾病，涉及线粒体功能障碍、氧化应激和免疫介导机制。有效治疗 SAMS 需要对患者的症状、风险因素和用药史进行全面评估，并考虑其他治疗方案。摘要虽然他汀类药物能有效降低心血管事件的风险，但其使用与一系列不良反应有关，包括 SAMS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.